GEMCITABINE AND CISPLATIN ± VELIPARIB FOR PANCREAS ADENOCARCINOMA AND A GERMLINE BRCA/PALB2 MUTATION

Share

Share on facebook
Share on linkedin
Share on twitter
Share on email

A cohort of 50 patients with untreated locally advanced or metastatic pancreatic ductal adenocarcinoma and a germline mutation in BRCA1/2 or PALB2 was randomized to receive gemcitabine/cisplatin with or without veliparib in this multicenter phase II trial. The response rate was numerically but not statistically superior in the veliparib triplet group. The median progression-free and overall survival were also similar between groups.

These results exceeded pre-study thresholds of efficacy, with particularly encouraging 2-year (31%) and 3-year (18%) survival rates for the entire cohort.

Gemcitabine plus cisplatin represents the optimal first-line option for patients with pancreatic cancer with these germline mutations.

https://www.practiceupdate.com/content/gemcitabine-and-cisplatin-veliparib-for-pancreas-adenocarcinoma-and-a-germline-brcapalb2-mutation/95639/11/1/1